CureVac Reports Q1 2025 Financials and Business Developments

CureVac announced its financial results and business updates for Q1 2025. The company reported €0.9 million in revenue, a significant decrease from €12.4 million in Q1 2024, primarily due to restructuring its partnership with GSK. Operating loss decreased to €54.7 million from €73.3 million in 2024.

Moving forward, CureVac has cleared a U.S. FDA Investigational New Drug application for its lung cancer candidate, with trials set for the second half of 2025. Furthermore, the glioblastoma study has completed enrollment, while decisions on moving to Phase 2 are expected later this year. Prophylactic vaccine efforts continue, with a focus on urinary tract infections.

Additionally, CureVac upheld core mRNA patents in Europe, which should bolster its position in ongoing litigation. The company ended Q1 with €438.3 million in cash, projecting stability through 2028.